End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
66 EUR | +0.15% |
|
+0.15% | -33.12% |
06-24 | RBC lowers target for Carl Zeiss Meditec to 85 euros - 'Outperform' | DP |
06-24 | UBS lowers Carl Zeiss Meditec to 'Neutral' - target to 71 euros | DP |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.08 times its estimated earnings per share for the ongoing year.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-33.12% | 6.52B | - | ||
+5.16% | 213B | B | ||
+9.62% | 188B | B- | ||
+31.18% | 157B | B- | ||
+33.37% | 113B | A- | ||
+3.46% | 64.85B | A- | ||
+1.51% | 49.1B | B+ | ||
-4.27% | 38.83B | A | ||
+0.88% | 35.6B | - | ||
+8.44% | 27.4B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AFX Stock
- 4AFX Stock
- Ratings Carl Zeiss Meditec AG